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Abstract
The year 2007 was marked by widespread adverse clinical responses to heparin use, leading to a global recall of potentially
affected heparin batches in 2008. Several analytical methods have since been developed to detect impurities in heparin
preparations; however, many are costly and dependent on instrumentation with only limited accessibility. A method based
on a simple UV-scanning assay, combined with principal component analysis (PCA), was developed to detect impurities,
such as glycosaminoglycans, other complex polysaccharides and aromatic compounds, in heparin preparations. Results
were confirmed by NMR spectroscopy. This approach provides an additional, sensitive tool to determine heparin purity and
safety, even when NMR spectroscopy failed, requiring only standard laboratory equipment and computing facilities.
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Introduction
Heparin, a sulfated glycosaminoglycan (GAG) present in several
mammalian and other vertebrate and invertebrate tissues [1,2,3,4],
has been an established anticoagulant drug for more than 60 years
and is widely used for the prevention and control of thrombotic
events owing to its interaction with a number of proteins of the
blood clotting cascade, notably antithrombin and thrombin. It
consists of a linear, highly sulfated polysaccharide chain comprising
repeating disaccharide units of 1,4 O-linked a-L-iduronic or b-D-
glucuronic acid, and a-D-glucosamine. The predominant substitu-
tion pattern comprises 2-O-sulfation of the iduronate residues and
N- and 6-O-sulfation of the glucosamine residues [5,6,7]. The
distribution of these sulfates in the polysaccharide chain provides
heparin an average of 3.5 negative charges per disaccharide unit [8].
Other substitution patterns are also possible, including N-acetylation
and 3-O-sulfation of the glucosamine, as well as non-sulfated
iduronate and b-D-glucuronate, and 2-O-sulfation of glucuronate,
providing considerable sequence heterogeneity [9] and making the
structural elucidation of heparin challenging.
The pharmacological activity of heparin arises from its
capability to bind and accelerate the activity of antithrombin
(AT) [10], which considerably enhances the inhibition of
coagulation factors Xa and IIa. The heparin anticoagulant effect
can be directly correlated to the inhibition of factor Xa by AT
[11], which catalyzes the conversion of prothrombin to thrombin,
decreasing thrombin generation and, ultimately, the formation of
a fibrin clot.
Pharmaceutical heparin is largely obtained from porcine
intestinal mucosa by a multi-step extraction process that involves
proteolysis, anion exchange chromatography or quaternary
ammonium complexes, ethanol precipitation and bleaching.
Throughout this process other naturally occurring GAGs, such
as chondroitin (CS), dermatan (DS) and heparan sulfates (HS), as
well as proteins and small molecules accompany heparin and,
additionally, heparin may be modified [12]. The removal of these
additional compounds incurs loss [13], which on an industrial
scale is an undesirable outcome. Since this process is quite
complex, it requires carefully executed procedures and effective
quality control monitoring to avoid the co-purification of
impurities and contaminating species.
Owing to the complex isolation and purification required, the
issue of heparin impurities has long been recognized and was first
brought up in 1955 when traces of phosphate were found in
commercial heparins [14]. Ethylenediaminetetraacetic acid
(EDTA) and histamine have also been identified in commercial
heparin [15,16], and the presence of EDTA has been associated
with increased bleeding effects [15].
In 1989, nuclear magnetic resonance spectroscopy (NMR) was
used to identify the presence of other GAGs in pharmaceutical
heparins [17]. Dermatan sulfate (DS) was found to be the most
common impurity comprising up to 10–15 percent of the polymer
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mixture. Again, in 2001, DS, sodium acetate and ethanol were
identified as frequent impurities in heparin preparations [18].
Additionally, in early 1990’s the outbreak of bovine spongiform
encephalopathy (BSE) resulted in the exclusion of materials
originating from ruminants for the production of heparin. Several
methods involving molecular biology and immunochemical ap-
proaches were used to check the raw materials used by heparin
manufacturers [19,20]. However, none of these issues led to any
reported adverse clinical responses, or resulted in significant number
of deaths.
In 2008, significant numbers of adverse clinical responses
associated with heparin use were first reported, leading to at least
149 deaths in the United States. Once again, using NMR and other
analytical methods, the major contaminant present in heparin
batches related to adverse clinical events was identified as an
oversulfated chondroitin sulfate (OSCS) [21]. Several papers were
then published regarding analytical approaches to assess heparin
purity [13,22,23,24,25,26]. However, many of these methods are
expensive, time consuming and/or require access to sophisticated
and costly instrumentation and facilities, making them difficult to
use for producers and regulatory authorities in many locations.
Recently, the ability of circular dichroism (CD), a UV-based
technique to differentiate GAGs effectively was demonstrated [5].
Differentiation was improved with the use of principal component
analysis (PCA), a powerful statistical tool that allows the
identification of patterns in any dataset and highlights their
similarities and differences. This approach has been used to extract
relationships from many forms of spectra and numerical data
related to GAGs [5,27,28,29].
In the present paper, we investigate the possibility of a simpler UV-
based technique - scanning UV spectroscopy, combined with PCA,
as a potential method for the assessment of heparin purity. The more
technically demanding and expensive NMR technique was also
employed as an external control of the effectiveness of the method.
Results
NMR confirmation of heparin purity
1H NMR was performed according to the USP heparin
monograph on 8 heparin samples in order to assess their purity
to establish a controlled baseline for subsequent analysis. Special
attention was given to the spectral region in which the N-acetyl
group appears ,2.00 p.p.m. Typical 1H NMR spectra of
unfractionated heparins (UFHs a, b, c and d) are shown in
Figure 1A. Major signals correspond to the trisulfated disaccharide
(a-L-iduronate 2-O-sulfate R4 a-D-glucosamine N,O-disulfate),
which is the prevalent disaccharide repeating unit in heparin. No
additional N-acetyl group signal was observed, leading to the
conclusion that these preparations are free of other GAG species.
Figure 1B shows the presence of an additional signal, in the 1H
NMR spectra of samples e, f, g and h, at 2.15 p.p.m,
corresponding to N-acetyl groups distinct from that of heparin
N-acetyl signals at 2.04 p.p.m and from those of DS at 2.08 p.p.m.
This additional signal corresponds to the N-acetyl group of the
previously described OSCS, which was shown to be the major
contaminant present in heparin preparations related to adverse
clinical responses [21]. Also, the 1H NMR spectra of the
contaminated samples displayed strong signals, 7.4–7.8 p.p.m,
consistent with aromatic compounds, which were further charac-
terized as benzyl alcohol (Figure S1).
Scanning UV spectroscopy is able to identify other GAG
impurities in heparin samples
The features in the UV spectra [190–320 nm] of GAGs arise
predominantly from electronic transitions in the carboxylate groups
of the uronate residues and the N-acetyl chromophores in the
glucosamine residues (nRp* and pRp * transitions), the carboxylate
chromophore being responsible for the majority of the spectral
features. Typical scanning UV spectra of samples containing
carboxylic acid groups were observed with the highest peak around
190 nm, arising from the electronic transition occurring in the
carboxylate chromophore of iduronate and glucuronate present in
the GAG chains. Two distinct groups were easily identified; the
pure samples (a, b, c and d) displayed only one sharp band from
190–210 nm while, on the other hand, the contaminated samples (e,
f, g and h) displayed a much broader signal around 200–220 nm
and an additional broad signal around 240–260 nm with a maxima
at 257 nm (Figure 2A). This latter signal corresponds to electronic
transitions arising from aromatic compounds being comparable to
the UV scanning spectrum of benzyl alcohol [30].
Figure 1. NMR analysis of heparin samples. (A) 1H NMR spectra of pure heparin samples. (B) 1H NMR spectra of contaminated heparin samples.
From bottom to top samples a, b, c and d (A) and e, f, g and h (B). Signals due to the contaminants are highlighted by asterisks. ANS, 2-deoxy-2-
sulfoamino-D-glucopyranose; A3S, 2-deoxy-3-O-sulfo-2-amino-D-glucopyranose; ANAC, 2-deoxy-2-acetylamino-D-glucopyranose; I2S, 2-O-sulfo-
iduronic acid; G, glucuronic acid; I, iduronic acid.
doi:10.1371/journal.pone.0015970.g001
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The resulting UV spectra were next analyzed by PCA, in which
the first two components described 99.54% of the variance
(Figure 2B). The first principal component was sufficient to
differentiate pure from contaminated samples, while the second
principal component picked out the differences between the two
groups (Figure 2C). The cluster analysis performed on the loading
plot (Figure 2D) produced two distinct clusters, one comprising
pure samples and the other containing contaminated samples,
demonstrating that the analysis of scanning UV spectra by PCA is
a powerful method to differentiate pure from impure heparin
preparations.
Scanning UV spectroscopy also differentiates other GAGs
from heparin preparations
In addition to identifying semi-synthetic contaminants, the
method was able to detect the presence of other glycosaminogly-
cans impurities, including CS, DS, HS and heparin by-products
(Figure 3A). The presence, in higher levels, of N-acetyl
Figure 2. UV spectra, loading plot and Hierarchical cluster analysis of heparin samples. (A) Overlay of heparin samples scanning UV
spectra. (B) Scree plot for PCA of the UV-scan spectra. (C) Component plot. (D) Hierarchical cluster analysis performed on the loading plot. Samples
a–d represent pure heparin samples and e–h are the commercial contaminated heparins.
doi:10.1371/journal.pone.0015970.g002
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chromophores at slightly different chemical shift positions in the
1H spectra of other GAGs resulted in UV spectra which were
distinct from that of heparin.
PCA analysis of these spectra revealed that the first three
principal components described 97.19% of the variance, and these
were used to differentiate the samples (Figure 3B). Component 1
was able to differentiate pure heparin samples from other GAGs
and contaminated samples, while components 2 and 3 differen-
tiated pure from impure and contaminated heparin (Figure 3C).
The presence of semi-synthetic sulfated GAGs in contaminated
heparin samples produced a unique spectrum, which was easily
differentiated by PCA of the UV spectrum and shown by the
cluster analysis (Figure 3D).
Scanning UV spectroscopy detects the presence of non-
mammalian polysaccharides in heparin preparations
A variety of polysaccharides with charge properties, molecular
weight and anticoagulant activities similar to heparin are well
known. This led us to test whether scanning UV spectroscopy
combined with PCA would be able to differentiate pure heparin
Figure 3. Multivariate analysis of UV spectra of heparins and other GAGs. (A) Overlay of GAGs scanning UV spectra. (B) Scree plot of
components. (C) Plot of the first three components. (D) Hierarchical cluster analysis performed on the loading plot. Samples a–d represent pure
heparin samples; e–h are the commercial contaminated heparins, i–k and t represent DS, C4S, C6S and HS respectively; l–m are SOSCS and IHC; r–s are
heparin spiked with 5 and 10% of heparin-by product; u–v correspond to heparin spiked with 5 and 10% of HS.
doi:10.1371/journal.pone.0015970.g003
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from heparin that had been spiked with two non-mammalian
polysaccharides. The presence of both contaminants produced two
extra bands at 215–240 nm and 270–290 nm in the UV spectra
(Figure 4A).
Further analysis of the UV spectra using PCA showed that the
first two principal components described 99.59% of the variance
present in the data set (Figure 4B). The component score plot for
component 1 (Figure S2A) shows that this variance arises from
differences in the electronic transition occurring mainly in the
carboxylate groups, a fact that may arise from structural variability
among heparin preparations. However, the component score plot
for component 2, which accounts for only 6.09% of the variance,
indicated that the differentiating features are the extra bands from
215–240 nm and 270–290 nm (Figure S2B). The two components
were used to differentiate the samples (Figure 4C) and for the
cluster analysis (Figure 4D).
Figure 4. Multivariate analysis of UV spectra of heparin spiked with non-mammalian polysaccharides. (A) Overlay of heparin
preparations scanning UV spectra. (B) Scree plot of components. (C) Component plot. (D) Hierarchical cluster analysis performed on the loading plot.
Samples a–d represent pure heparin samples; n–p correspond to heparin spiked with 5 and 10% of SA respectively; g–h are heparin spiked with 5 and
10% of SG.
doi:10.1371/journal.pone.0015970.g004
Heparin Purity and Safety Determination
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15970
Combination of scanning UV spectroscopy and PCA
detects as low as 0.1% contaminants in heparin samples
The method was able to successfully detect impurities and
contaminants in heparin. The ability of the method to identify
only traces of contaminants was then assessed.
In order to address this question, a pure heparin sample was
spiked with 0.1, 0.3, 1, 1.3, 1.6, 2, 3 and 5% (w/w) of the isolated
heparin contaminant (IHC) and their respective scanning UV
spectra recorded. PCA analysis of the UV spectra revealed that
this approach was able to distinguish pure heparin from the spiked
heparin preparations (Figure S3A and B), yet this differentiation
was questionable for contaminant levels lower than 1%, since
spectral fluctuation could mask the results. For this reason,
multiple spectra were recorded for each sample (Figure 5A). The
resulting UV spectra were next analyzed by PCA, in which the
first two components described 99.59% of the variance (Figure 5B).
Indeed, as shown by the PCA analysis, there was significant
spectral fluctuation, however, the variability occured within the
Figure 5. UV spectra, loading plot and Hierarchical cluster analysis of heparin preparations. (A) Overlay of heparin preparations UV-scan
spectra. (B) Scree plot of components. (C) Component plot. (D) Hierarchical cluster analysis performed on the loading plot.
doi:10.1371/journal.pone.0015970.g005
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sample groups as shown by the loading plot (Figure 5C) and cluster
analysis (Figure 5D).
Discussion
The issue of heparin impurities has been well-known since 1955,
when the first paper was published regarding the identification of
phosphate in heparin preparations [14]. Subsequently, mixtures of
glycosaminoglycans and other organic and inorganic impurities
were found in pharmaceutical heparin preparations [15,16,17,18].
With the outbreak of BSE this matter resurfaced, however, none of
these problems led to a major heparin recall across the globe.
In 2008, health authorities in the United States received several
alerts regarding acute hypersensitivity reactions due to the use of
heparin in patients undergoing dialysis. These reports led to a
major recall, first in the USA and then Europe, of heparin batches,
heparin coated medical devices, and lock flush-injections that used
heparin as the active pharmaceutical ingredient.
By June of the same year Guerrini and colleagues had identified
and characterized the major contaminant in heparin batches as an
oversulfated chrondroitin sulfate (OSCS) [21], a compound that
does not exist naturally, which led to the conclusion that the
contamination was deliberate. Subsequently, several other groups
published papers on the same subject using a wide variety of
methods [23,24,25,26,31]. More recently, the contaminant was
claimed to compromise not only OSCS but a mixture of other
chemically sulfated GAGs, probably arising from waste generated
throughout the heparin production process [22]. Also, the
mechanism in which the OSCS contaminant caused the
anaphylactoid responses was characterized [32], and recently
how these semi-synthetic GAGs activate the complement system
and how they affect GAG-dependent cell signaling pathways have
also been investigated [33].
The methods capable of identifying impurities and suitable for
the assessment of heparin purity and safety are often based on
NMR, which is a very time consuming and expensive technique
since it relies on technically complicated procedures using
expensive machines that are not available in many laboratories,
a fact that makes it difficult for all but the best equipped
laboratories to monitor heparin preparations on a large scale.
Moreover, the presence of significant amounts of DS in drugs
constituted by GAG mixtures raises the limit of detection of OSCS
at 500MHz from 0.05% to 0.2% [12]. In addition, peaks can shift
depending on the counter ion present, i.e. calcium versus sodium,
as well as the exact sulfation pattern of the heparin and/or the
contaminants [34], despite the fact that NMR based methods were
developed to specifically monitor the presence of oversulfated
GAGs species, which exclude a great number of non-N-acetylated
potential contaminants with charge properties, molecular weight
and anticoagulant activities similar to heparin.
Recently, the combination of circular dichroism, an UV-based
spectroscopy, with multivariate analysis methods have allowed
differentiation of low molecular weight heparins obtained by
different methods of production, as well as naturally occurring
GAGs [29]. This showed in principle that relatively simple
methods were able to differentiate between members of this class
of highly complex carbohydrate.
In the present paper, scanning UV spectroscopy - a very simple
technique requiring only a standard scanning UV spectropho-
tometer, in combination with PCA -, was used to assess heparin
purity on a series of samples whose purity had been confirmed
previously by 1H NMR. The method was also capable of
distinguishing pure from commercial contaminated heparin
samples and heparin spiked with other GAGs, as well as non-N-
acetylated polysaccharides, which 1H NMR have failed to identify
[12,31]. This differentiation was accomplished by virtue of the
carboxylate chromophore of iduronate and glucuronate in the
GAGs and the presence of N-acetyl groups, in higher levels and in
slightly different environments in CS, DS, and HS. Other
chromophores, such as the carboxylate groups in non-GAG
polysaccharides as sodium alginate and pyruvate in sulfated
galactans provided additional features to the UV-spectra. UV
spectroscopy is also highly sensitive to the electronic transitions
that occur within protein and aromatic impurities; an example of
the latter are the signals present on the UV and 1H NMR spectra
of the contaminated heparin samples (Figure 2A and 6), being
them further identified as belonging to benzyl alcohol.
Benzyl alcohol, a bacteriostatic agent found in many parental
preparations, has been associated with adverse clinical events
[35,36], for this reason the use of parental preparations containing
such preservative agents is restricted. The effect of benzyl alcohol
on vascular endothelial cells (VEC) was evaluated, employing a
cell viability assay and revealing that benzyl alcohol is highly toxic
to VEC (Figure S4); therefore, together with the fact that the latest
bulletin regarding anticoagulant heparin solution states that it
contains no antimicrobial agents [37], specific guidelines regarding
the presence of this compound on heparin vials should be
readdressed since.
The heparin contamination crisis reinforced the idea that the
purity and relative uniformity of complex mixtures such as heparin
requires the use of multiple, orthogonal analytical techniques [38].
However the adoption of the currently available techniques by
heparin manufacturers will cause increased production costs and,
ultimately, higher prices for the final product, therefore the search
for cheaper and more versatile analytical approaches such as that
presented here is of great importance. Taken together, the results
showed that this simple approach may be used as an additional
tool to verify heparin purity and safety. Furthermore, this
approach allows the establishment of a database of standard
heparins against which any given sample could be cross-checked,
providing the level of similarity among them and highlighting their
similarities and dissimilarities (presence of contaminants), besides
the determination of whether a heparin sample should be
Figure 6. Selected 1H NMR region showing the benzyl alcohol
signals found on the contaminated heparin samples spectra.
Signals due to benzyl alcohol are highlighted by asterisks. ANAC, 2-
deoxy-2-acetylamino-D-glucopyranose; ANS, 2-deoxy-2-sulfoamino-D-
glucopyranose; I2S, 2-O-sulfo-iduronic acid; I, iduronic acid.
doi:10.1371/journal.pone.0015970.g006
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subjected to the full quality assessment by highly sophisticated,
modern and expensive spectroscopic methods.
Materials and Methods
Polysaccharides
Contaminated heparin samples were the recalled heparin lots
withdrawn from the clinical use in the Hemodialysis Unit from the
Loyola University Hospital in Maywood, IL or purchased from the
Brazilian market. Semi-synthetic (SOSCS) and isolated heparin
contaminant (IHC) were prepared as previously described [25].
Pure heparin samples were a gift from Dr. Valentina Baigorria
(Kim Master Produtos Quı´micos Ltd, Brazil) and Gentium SpA
(Villa Guardia (CO), Italy). The GAGs and polysaccharides
chondroitin 4-sulfate (C4S), chondroitin 6-sulfate (C6S), dermatan
sulfate (DS), and sodium alginate (SA) were purchased from
Sigma-Aldrich (St. Louis, MO). Heparan sulfate (HS) and sulfated
galactans (SG) were purified as previously described [39,40].
These compounds, including the contaminants, can be distin-
guished by their electrophoretical mobility in agarose gel (Figure
S5A and B) assessed as previously described [Reference S1].
Nuclear Magnetic Resonance
1H NMR was performed as described in the USP unfracionated
heparin (UFH) monographs with residual water signal suppression
[41]. Briefly, samples of 20 mg/ml in deuterium oxide (99,9%,
Cambridge Isotope Laboratories Inc, Andover, MA, USA) were
used for the acquisition of a free induction decay (FID) using 16
scans, a 90u pulse and 20 s delay at 25uC in a Bruker DRX-500
spectrometer.
Scanning UV spectroscopy
Scanning UV spectroscopy was performed on Perkin-Elmer
Lambda 25 UV/VIS spectrometer. Samples of 1 mg/ml in water
were scanned from 190 to 320 nm with 1 nm resolution at
120 nm/min. The resulting spectra were saved as ASC files for
subsequent analysis using PCA.
Factor Analysis
Factor analysis, of which principal component analysis is an
example, is used to uncover the latent structure (dimensionality) of a
complex data set and encapsulate the crucial information, while
eliminating noise. PCA performs the optimum co-ordinate rotation
to align the axes so that the variance within the data is maximized.
This transforms a set of previously correlated variables into a set of
uncorrelated ones, which are linear combinations of the original
variables. The linear combination that extracts the maximum
variance from the data is termed the principal component. Once
this is found, this is removed and the process repeated to identify the
next principal component. This continues until all the variance in
the data has been explained (in practice, this is not achieved because
of residual noise and the process is terminated).
Multivariate Analysis
PCA and Cluster analysis were conducted using the software R:
A Language and Environment for Statistical Computing (R
Foundation for Statistical Computing, Viena, Austria. http://
cran.r-project.org/), with prior mean centering.
Definitions
Components represent the underlying dimensions that summarize
or account for the original set of observed data. Component loadings
are the correlation coefficients between variables and factors. The
squared factor loadings indicate the percentage of the variance in
the original variable that is explained by a factor. Component scores
are a composite measure created for each observation on each
factor extracted in the factor analysis.
Supporting Information
Figure S1 Aromatic component identification via NMR spec-
troscopy. Bottom to top; Selected 1H NMR spectrum of Benzyl
Alcohol and contaminated heparin sample. Note the signal
correspondence on both spectra. ANS, 2-deoxy-2-sulfoamino-D-
glucopyranose, I2S, 2-O-sulfo-iduronic acid.
(TIF)
Figure S2 Component score plot of heparin spiked with non-
mammalian (sodium alginate and sulfated galactan) polysaccha-
rides. (A) Component 1 score plot. (B) Component 2 score plot.
(TIF)
Figure S3 Loading plot and Hierarchical cluster analysis of
heparin preparations. (A) Plot of the first two components. (B)
Hierarchical cluster analysis performed on the loading plot. UFH,
Unfracionated heparin; SUFH, Spiked unfracionated heparin.
(TIF)
Figure S4 Benzyl Alcohol Cytotoxicity. Cytotoxicity was
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromide (MTT) assay. For this assay, 105 vascular
endothelial cells were seeded in 96-well plates and cultured for 2
days. The medium was removed and fresh medium containing
10% FBS and different amounts of Benzyl Alcohol or only fresh
medium (control) were added being the cells maintained for
24 hours (37uC, 5% CO2). Afterwards, the cells were washed with
PBS and serum-free medium containing MTT (0.5mg/mL) was
added. After 2 hours of incubation, isopropanol extraction was
performed and the absorbance measured at 570 nm with an
ELISA reader (ELx800 BioTek Instruments, Winooski, VT).
(TIF)
Figure S5 Agarose gel electrophoresis in different buffer systems
[Reference S1]. Briefly, aliquots (5 mg) of sGAGs were applied to a
0.6% agarose gel and ran for 1 h at 100 V. The sGAGs in the gel
were fixed with 0.1% N-cetyl-N,N,N-trimethylammonium bromide
solution. After 2 h, the gel was dried and stained with 0.1%
toluidine blue in acetic acid/ethanol/water (0.1:5:5, v/v). (A)
0.05M 1,3-diaminopropane acetate buffer pH 9. (B) Discontinu-
ous barium acetate/1,3-diaminopropane acetate buffer system.
CUFH, contaminated unfracionated heparin; PUFH, porcine
unfracionated heparin; BUFH, bovine unfracionated heparin;
sGAG, sulfated glycosaminoglycans; SOSCS, semi-synthetic over-
sulfated chrondroitin sulfate; ICH, isolated heparin contaminant;
Hep, heparin; F, fast moving component; I, intermediate moving
component; S, slow moving component; Org., origin; CS,
chrondroitin sulfate; DS, dermatan sulfate; HS, heparan sulfate.
(TIF)
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